Press Releases

Ernst & Young to co-host new symposium focused on the revolution in product reimbursement strategies in health care

PHILADELPHIA, Oct. 10, 2012 /PRNewswire/ -- Ernst & Young today announced that it will be co-hosting the first annual Real Endpoints Symposium, which will bring together senior executives from leading life sciences companies, payers, providers, and policy makers to discuss new solutions and innovative strategies to address the rapidly changing reimbursement environment in healthcare. This unique forum, entitled Disruptors: revolutionizing product reimbursement strategy, will be co-hosted by Real Endpoints, and will take place November 1-2, 2012 at the Hyatt Regency in Philadelphia, PA.

"Given the financial pressures facing the global health care ecosystem, it is clear that life sciences companies can no longer simply rely on great science for the successful reimbursement of their products," said Glen Giovannetti, Global Life Sciences Leader for the Ernst & Young organization. "We are delighted to join with Real Endpoints in convening an impressive group of recognized innovators at the forefront of the evolving reimbursement landscape to discuss the challenges, opportunities and collaborative solutions for all key stakeholders in health care."

This inaugural, two day event will draw upon the insights and expertise of leading payers, policymakers and industry leaders who are at the forefront of the reimbursement revolution. Sessions will focus on the seven crucial product development and commercial issues that companies must confront over the next 24 months and beyond, including:

  1. Disintermediating pharma: the pivotal new research role of payers in proving the value of emerging technologies
  2. Reimbursement bundling: the dramatic implications for product development and commercialization with the decline of fee-for-service medicine
  3. Getting off track – why what we believed about personalized medicine is only half true
  4. The evolving rules of comparative effectiveness and who will ultimately approve them
  5. Real world evidence: when it works, when it doesn't, and what payers & providers will require
  6. Adherence – why it's been such a bust for payers and for pharma ... and why everyone now needs to take a second look.
  7. Payer/pharma risk-sharing – why it hasn't worked ... but why (and when) it will

Scheduled presenters at the symposium include:     

Lewis Sandy, MD
SVP, Clinical Advancement, UnitedHealth

Carolyn Clancy, MD
Director, Agency for Healthcare Research and Quality

Rob Epstein, MD
Former CMO, Medco and president, Medco Research and Health Policy, UPenn

Ira Klein, MD
Chief of Staff to CMO, Aetna

Martin Mackay, PhD
President, R&D, AstraZeneca

Jack Bailey
SVP, Policy, Payers & Vaccines, GlaxoSmithKline

Jeff Berkowitz
SVP, Pharmaceutical Development & Market Access, Walgreen Co

Michael Sherman, MD
CMO, Harvard Pilgrim

Robert Galvin
CEO, Equity Healthcare

Zeke Emanuel, MD
Chairman, Dept of Medical Ethics

William Shrank
Director, Rapid Cycle Innovation, CMS

Annalisa Jenkins, MD
EVP, Head of Global Development, Merck Serono

Steve Wooding
VP, Head of Market Access, Janssen EMEA, J&J

To register for Disruptors: revolutionizing product reimbursement strategy, please visit

Follow the conversation at and on Twitter with #RESymp

About Real Endpoints
Real Endpoints ( is building a unique information platform to reveal insights about the changing world of product reimbursement.  RE's business portfolio includes Reimbursement Intelligence LLC, a leading market-research company (, and several proprietary databases now in development. Our goal: support the process of innovation by helping our pharma, device, payer and provider customers improve the quality and cost of the services and products they provide, realize greater value, and deliver improved health outcomes.

About Ernst & Young's Global Life Sciences Center
Ernst & Young's Global Life Sciences Center brings together a worldwide team of professionals to help life sciences companies address their challenges at every stage of development. From the emerging biotech or medtech firm to the well-established, global pharmaceutical company, our industry teams bring deep experience in providing assurance, tax, transaction and advisory services. The Center works to anticipate market trends, identify implications and develop points of view on relevant industry issues. Whether it's forming innovative alliances, improving operations, new regulations or exploring new markets, we can give you a clear perspective on how to drive value in an increasingly complex, competitive and risk-driven environment. It's how Ernst & Young makes a difference. For more information, please visit or email

About Ernst & Young
Ernst & Young is a global leader in assurance, tax, transactions and advisory services. Worldwide, our 167,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.

For more information, please visit

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. This news release has been issued by EYGM Limited, a member of the global Ernst & Young organization that also does not provide any services to clients.

Contact name: 

Michelle Sing

Greg Kelley


Ernst & Young LLP   

Feinstein Kean Healthcare





SOURCE Ernst & Young